ICICI Direct's research report on Alembic Pharma
Revenues grew 15% YoY to Rs 853 crore (I-direct estimate: Rs 830 crore) mainly on account of 45% YoY growth in the US to Rs 290 crore (I-direct estimate: ~Rs 233 crore) led by one-off and volume driven growth. Excluding one-off, US sales grew 30% YoY EBITDA margins improved 215 bps YoY to 20.3% (I-direct estimate: 22.5%) mainly due to lower other expenditure. EBITDA increased 29% YoY to Rs 173 crore vis-à-vis I-direct estimate of Rs 187 crore Net profit increased a mere 1% YoY to Rs 94 crore (I-direct estimate of Rs 130 crore). Growth in the operational performance was largely offset by higher depreciation & tax rate (27.3% vs. 14.7% in Q4FY17).
Outlook
We believe this is fraught with a new set of challenges. The benefits are most likely to be back-loaded. Immediate cash burn is likely to weigh on sentiments in the near term. Accordingly, we arrive at our new target price of Rs 460 based on 18x FY20E EPS of Rs 25.5.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
